Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Dermatologic 2Breast 2Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 25Lymphoma 13Leukemia, Myeloid, Acute 10Ovarian Neoplasms 9Neoplasm Metastasis 9Lymphoma, Follicular 9Leukemia 9Stomach Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neuroblastoma 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, B-Cell, Marginal Zone 6Multiple Myeloma 5Lymphoma, Large B-Cell, Diffuse 5Kidney Neoplasms 5Hodgkin Disease 5Burkitt Lymphoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Triple Negative Breast Neoplasms 4Recurrence 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Lymphoma, Large-Cell, Immunoblastic 4

Interventions

pembrolizumab 7fludarabine 4Nivolumab 4Cyclophosphamide 4Radiation 3Interleukin-2 3talimogene laherparepvec 2poly ICLC 2budigalimab 2aldesleukin 2Radiotherapy 2Ipilimumab 2Everolimus 2CTLA-4 Antigen 2zimberelimab 1venetoclax 1veliparib 1vatalanib 1tocilizumab 1temsirolimus 1rovalpituzumab tesirine 1prednylidene 1pentetreotide 1lorvotuzumab mertansine 1glucopyranosyl lipid-A 1flt3 ligand protein 1deltacortene 1cixutumumab 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Merkel Cell × aldesleukin × Clear all
NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
12 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡